Literature DB >> 10906172

Human immunodeficiency virus and AIDS: insights from animal lentiviruses.

R J Miller1, J S Cairns, S Bridges, N Sarver.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10906172      PMCID： PMC112239          DOI： 10.1128/jvi.74.16.7187-7195.2000

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


× No keyword cloud information.
  52 in total

1.  A consensus sequence for a functional human endogenous retrovirus K (HERV-K) dUTPase.

Authors:  J M Harris; R H Haynes; E M McIntosh
Journal:  Biochem Cell Biol       Date:  1997       Impact factor: 3.626

2.  Lessons from the cat: feline immunodeficiency virus as a tool to develop intervention strategies against human immunodeficiency virus type 1.

Authors:  J H Elder; G A Dean; E A Hoover; J A Hoxie; M H Malim; L Mathes; J C Neil; T W North; E Sparger; M B Tompkins; W A Tompkins; J Yamamoto; N Yuhki; N C Pedersen; R H Miller
Journal:  AIDS Res Hum Retroviruses       Date:  1998-06-10       Impact factor: 2.205

Review 3.  Control of RNA initiation and elongation at the HIV-1 promoter.

Authors:  K A Jones; B M Peterlin
Journal:  Annu Rev Biochem       Date:  1994       Impact factor: 23.643

4.  Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants.

Authors:  D E Mosier; G R Picchio; R J Gulizia; R Sabbe; P Poignard; L Picard; R E Offord; D A Thompson; J Wilken
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

5.  Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo.

Authors:  T Lee; G S Laco; B E Torbett; H S Fox; D L Lerner; J H Elder; C H Wong
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

6.  Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM).

Authors:  T M Fletcher; B Brichacek; N Sharova; M A Newman; G Stivahtis; P M Sharp; M Emerman; B H Hahn; M Stevenson
Journal:  EMBO J       Date:  1996-11-15       Impact factor: 11.598

7.  Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme.

Authors:  M Bouhamdan; S Benichou; F Rey; J M Navarro; I Agostini; B Spire; J Camonis; G Slupphaug; R Vigne; R Benarous; J Sire
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

8.  Immune responses are required to terminate viremia in equine infectious anemia lentivirus infection.

Authors:  L E Perryman; K I O'Rourke; T C McGuire
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

9.  Gag protein epitopes recognized by ELA-A-restricted cytotoxic T lymphocytes from horses with long-term equine infectious anemia virus infection.

Authors:  W Zhang; S M Lonning; T C McGuire
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

10.  An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein.

Authors:  N Madani; D Kabat
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103
View more
  25 in total

1.  Vaccination with an inactivated virulent feline immunodeficiency virus engineered to express high levels of Env.

Authors:  Margaret J Hosie; Dieter Klein; James M Binley; Thomas H Dunsford; Oswald Jarrett; James C Neil; Elzbieta Knapp; Simone Giannecchini; Donatella Matteucci; Mauro Bendinelli; James A Hoxie; Brian J Willett
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

2.  Evolution of the long terminal repeat and accessory genes of feline immunodeficiency virus genomes from naturally infected cougars.

Authors:  Mary Poss; Howard Ross
Journal:  Virology       Date:  2007-09-29       Impact factor: 3.616

Review 3.  Going wild: lessons from naturally occurring T-lymphotropic lentiviruses.

Authors:  Sue VandeWoude; Cristian Apetrei
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

4.  Feline lentivirus evolution in cross-species infection reveals extensive G-to-A mutation and selection on key residues in the viral polymerase.

Authors:  Mary Poss; Howard A Ross; Sally L Painter; David C Holley; Julie A Terwee; Sue Vandewoude; Allen Rodrigo
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

5.  Uracil-directed ligand tethering: an efficient strategy for uracil DNA glycosylase (UNG) inhibitor development.

Authors:  Yu Lin Jiang; Daniel J Krosky; Lauren Seiple; James T Stivers
Journal:  J Am Chem Soc       Date:  2005-12-14       Impact factor: 15.419

6.  Variation in Intra-individual Lentiviral Evolution Rates: a Systematic Review of Human, Nonhuman Primate, and Felid Species.

Authors:  Emma Krakoff; Roderick B Gagne; Sue VandeWoude; Scott Carver
Journal:  J Virol       Date:  2019-07-30       Impact factor: 5.103

7.  Neuropathology associated with feline immunodeficiency virus infection highlights prominent lymphocyte trafficking through both the blood-brain and blood-choroid plexus barriers.

Authors:  Gavin Ryan; Terence Grimes; Brenda Brankin; Mohamad J E M F Mabruk; Margaret J Hosie; Oswald Jarrett; John J Callanan
Journal:  J Neurovirol       Date:  2005-08       Impact factor: 2.643

8.  Primate and feline lentivirus vector RNA packaging and propagation by heterologous lentivirus virions.

Authors:  M T Browning; R D Schmidt; K A Lew; T A Rizvi
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

9.  Evolutionary study of leporid CD4 reveals a hotspot of genetic variability within the D2 domain.

Authors:  Patricia de Sousa-Pereira; Joana Abrantes; Hanna-Mari Baldauf; Oliver T Keppler; Pedro J Esteves
Journal:  Immunogenetics       Date:  2016-03-15       Impact factor: 2.846

10.  Classic AIDS in a sooty mangabey after an 18-year natural infection.

Authors:  Binhua Ling; Cristian Apetrei; Ivona Pandrea; Ronald S Veazey; Andrew A Lackner; Bobby Gormus; Preston A Marx
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.